A Phase II Clinical Trial Evaluating DCVax®-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (GBM).


Study Number:


Principal Investigator:

Addtional Investigators:
Ady Kendler
Christopher M McPherson
Ronald E Warnick


University Hospital


The goal of this clinical trial is to assess the activity and safety of an investigational agent called DCVax-Brain which is made from the patient’s own blood cells which have been exposed to the patients own tumor tissue. Approximately 160 patients will receive the DCVax-Brain treatment and 80 control patients will receive a placebo (an inactive substance). Comparison of survival times and tumor growth between patients receiving the DCVax-Brain and the patients receiving the placebo will be used to determine whether this experimental treatment has had an impact on the course of this disease. The purpose of this clinical trial study is to determine whether DCVax-Brain can slow the growth and recurrence of your brain tumor and whether DCVax-Brain can extend overall survival. Other goals of the study are to test the safety and activity of DCVax-Brain and to determine whether the study agent causes an immune response (how your body recognizes and defends itself against substances that appear foreign and harmful to your body) against your cancer cells as compared to standard treatment or another experimental treatment. The clinical trial will consist of three phases: the initial evaluation phase (also known as the screening phase), the active treatment phase, and the follow-up phase. During the evaluation phase you will undergo some testing to indicate whether you can participate. The next phase, the active treatment phase, is when patients are treated with DCVax-Brain or placebo. During this phase, which lasts up to 36 months, you will be asked to return to the clinic once every two months for MRIs and other tests to determine how you are doing. During the follow-up phase, which starts after the 36 months is completed or after you leave the trial for any reason, you and/or a designated contact will be contacted every third month to ask how you are doing for the rest of your life. About 240 patients will take part in this study at various sites.  About thirty 30 people will take part in this study at The University of Cincinnati.

To be eligible for the study you must be 18 years or older and have a brain tumor.

For more information, please contact Alison Kastl, BS, CCRC, Director of Clinical Trials, at kastla@ucmail.uc.edu or (513) 584-0436.

This entry was posted in . Bookmark the permalink. Both comments and trackbacks are currently closed.
  • Print This Page
  • Make an Appointment: Schedule Now
  • UCNI Weekly Blog
  • Hope Stories

    • Jim’s Story: Pituitary Tumor

      Jim's Story: Pituitary Tumor One turn of events led to another, and so it was that Jim, and not his wife, took Jim’s 87-year-old father to his appointment with the dermatologist for the first time. And so it was that the dermatologist was not...
    • Doc’s Story: Metastatic Brain Tumors

      Doc’s Story: Metastatic Brain Tumors First there were headaches. Bad ones. Migraines, probably. Then, one day in mid-May, 2010, his knee, foot and arm went numb on his left side. Darrell “Doc” Rodgers, the 700WLW radio personality, feared he was having a stroke. In the emergency...
    • Joe’s Story: Oligodendroglioma

      Joe calls it a miracle and a gift from “a higher power.” Others might call it a fortuitous turn of fate. Either way, Joe’s experience embodies a reversal of fortune that is both wonderful and startling. Once a man with...
    • Jerry’s Story: Spinal Tumor

      Jerry's Story: Spinal Tumor On an ordinary day in February 2009, John M. Tew, MD, got one of the true surprises of his career. He was seeing patients in his Mayfield Clinic office on the University of Cincinnati medical campus when an unexpected guest...
    • Kevin’s Story: Acoustic Neuroma

      Kevin's Story: Acoustic Neuroma Kevin was in his mid-40s when he began to notice that he wasn’t hearing quite as well as in the past. But the change was gradual, so he didn’t worry about it. A few years went by, and the hearing...
    • Bob’s Story: Glioblastoma

      Bob's Story: Glioblastoma Bob’s story blends coincidence with collaboration and hope. The coincidence involves the 62-year-old West Chester man’s best buddy, “Jake,” a 165-pound...
    • Lynne’s Story: Brain Metastasis

      Lynne's Story: Brain Metastasis Semiretired and working part-time at a restaurant, Lynne knew something was amiss when she looked at the cash register and then struggled to make her hands produce the correct amount of change. Could she have suffered a stroke? Lynne pushed the...
    • Blake’s Story: Medulloblastoma

      Blake's Story: Medulloblastoma Blake knew he was in the right hands the moment he saw the surgeon’s wrists. Dr. John M. Tew, Blake’s neurosurgeon, was wearing one of Lance Armstrong’s yellow LiveStrong cancer bracelets. So was Blake. Dr. Tew, who was also sporting...
    • Brian’s Story: Meningioma

      Brian's Story: Meningioma “Carefree” is the word Brian uses to describe his life back then. He was 39 years old, happily married and the father of three children under the age of 5. “Life was busy, but that felt normal,” he says, reflecting. “The only...
    • John’s Story: Glioblastoma

      John's Story: Glioblastoma John, a retired painter and carpenter, is a tall, solidly built man with a strong inclination toward getting things done. A former Vista volunteer who was equally comfortable running a food co-op in an underserved neighborhood or standing near the...
    • Dr. Mike’s Story: Glioblastoma

      Dr. Mike's Story: Glioblastoma Nearly two years after receiving a diagnosis of brain cancer, Dr. Michael Wood continues to attack his disease with wellness. In addition to surgery, radiation, chemotherapy and strong family support, the Cincinnati otolaryngologist has worked hard to provide his own...
    • Sandra’s Story Glioma

      Sandra's Story Glioma Sandra (Sandy) is a smiling, breathing reminder that hope exists for patients with even the most challenging type of brain tumors. Nine years ago, when Sandy was first told that she had six months to live, she stared back blankly...